搜索到 1000 条关于 62c텔레그램sein07 ⊆마사지디비판매~% 的文章
-
内容创新、角度独特
-
2012.09.19 第三届中原呼吸与危重症医学论坛
经卫生部全国继续医学教育委员会批准，第三届中原呼吸与危重症医学论坛将于2012-04-07至2012-04-08召开。会议内容主要为学术讲座和病例讨论...：郑州大学第一附属医院3号楼会议中心报到时间：2012-04-07上午7：00~9：00报名截止日期：2012-04-03
-
第九届全国再生医学（干细胞与组织工程）学术研讨会暨第六届中华医学会医学工程学分会干细胞工程专业委员会年会
第九届全国再生医学（干细胞与组织工程）学术研讨会暨第六届中华医学会医学工程学分会干细胞工程专业委员会年会将于2013 年07 月12 日—07 月14 日在古都南京举行！特邀请国内外专家学者届时会聚一堂，共同规划再生医学研究蓝图，交流最新研究成果，把我国再生医学研究
-
2012.09.19 中华医学会第十七次全国医学信息学术会议
[ 重要日期 ]全文截稿日期： 2011-07-31[ 会务组联系方式...=2c96818c2f568c85012f8f92b5e7016f&type=newsColumn&css=blue&meetingId
-
2012.12.24 梅奥医院心律失常与心脏课程
官方网站：www.mayo.edu/cme/courses/results&findSpecialty=26D7E62C-F708-431C-82D902B2C3B9B6E7会议时间：2013/1/28-2013/2/1 地点：美国夏威夷茂宜岛
-
-
2016.04.04 ACC2016：非他汀降脂治疗专家共识要点一览
拉开帷幕，本届年会上，ACC 发布了关于动脉粥样硬化性心血管疾病（ASCVD）风险管理中降低低密度脂蛋白（LDL-C）的非他汀治疗专家共识（以下简称共识），本文为共识要点总结。1. 本篇共识旨在根据近期发表的临床研究证据对 ASCVD 高危患者降低 LDL-C 治疗推荐进行补充。2. 2013 ACC/AHA 血脂
-
-
2014.01.07 Post Traumatic Infections
幻灯片-01幻灯片-02幻灯片-03幻灯片-04幻灯片-05幻灯片-06幻灯片-07幻灯片-08
-
-
2014.01.07 Conducting Multicenter Studies in Anesthesiology
幻灯片-01幻灯片-02幻灯片-03幻灯片-04幻灯片-05幻灯片-06幻灯片-07幻灯片-08
-
-
2012.11.05 王巍：WCGC2012胃癌诊疗进展
-02-07-05-08-11-161st line treatment selection algorithm in advanced gastric
-
2012.12.05 2012年ADA糖尿病诊疗指南(三)
。DCCT试验采用的是短效和中效人胰岛素。尽管微血管并发症结局获得显著改善，胰岛素强化治疗的比率和严重低血糖发生率较高相关(62次／100患者一年)。自DCCT试验进行以来，一些速效和长效胰岛素类似物已研发出来。对于l型糖尿病患者而言，在A1C降低程度相同的背景条件下，这些类似物有更少的低血糖。l型糖尿病治疗建议
-
2011.12.30 研究表明11C-PD153035 PET/CT的分子成像技术能够预测EGFR-TKI治疗的非小细胞肺癌的生存率
with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated...)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging
-
-
2018.07.13 你问我答23期：β- 内酰胺类能否合用地塞米松？
本期问答：@dxy_aio5fn62运用头孢的患者能不能使用激素类的注射剂，因为胃肠外科病人术前会预防用头孢，而全麻时麻醉医生会忽略病人是否用头孢，习惯性运用地塞米松，泼尼松等，是否会发生双硫仑反应。参考答案：丁香园站友 @wangshuping :β- 内酰胺类和地塞米松不要一起使用，原因是：1、β- 内酰胺
-
-
2013.04.01 初治鼻咽癌的调强放疗
ICRU 62 定义-7双侧Ib淋巴结预防性照射-46IMRT治疗鼻咽癌-3靶区处方...图-38悬雍垂层面-24图-41C2上缘层面-23Level
-
2013.06.05 ASCO2013：一线治疗之使用阿霉素洗脱微球的TACE（DEB-TACE）+索拉非尼的2期临床试验
%), BCLC A/B/C (10%/28%/62%), ECOG 0/1 (52%/48%), HCV/HBV (44%/8%), mean tumor...无法治疗的肿瘤进展（TTUP）的中位时间为11.9月，其中BCLC A/B期患者为22.9月，C期患者为6.2月（P=0.01）。中位生存时间为24.5月（95
-
2012.09.19 首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
北京·2012年5月16-18日
上海·2012年5月21-23日尊敬的老师，您好！生理药代动力学模型（PBPK）在药物研发与监管中得到广泛应用意味着新时代的来临！它改变了动物试验和人体实验传统研究模式流程，指导制药企业项目决策及效率提高；FDA和EMA的使用及推荐，促使国外制药企业及学术单位相关研究者都在学习及掌握PBPK的应用。为促进我国在该领域的发展，力争与全球同步，凡默谷特邀美国Simulations Plus顶尖专家来华授课，让您了解及掌握PBPK知识、获悉国外最新应用、亲授多年使用经验，授课过程将以理论与实践相结合的形式进行。GastroPlus是由美国Simulations Plus公司研发的基于机制性生理模型的药代动力学、药效动力学(PBPK/PD)模拟软件，目前在FDA和几乎所有的全球顶尖制药公司中得到广泛应用，被誉为同类软件中的“黄金标准”。为确保培训效果，限额50人/班，第一轮通知发出后，已得到广大中国用户的积极响应和踊跃报名。报名从速！为何本次GastroPlus Workshop值得您参加？1）药物研发及监管中争相应用PBPK模型的时代已经来临！2）PBPK辅助药物研究可方便指导项目决策、节约成本、缩短时间；3）FDA已广泛采用PBPK模拟来制定法规和对新药及仿制药进行审批；4）FDA及各大制药企业对全球最权威的PBPK模拟软件GastroPlus倍加青睐；5）零距离接触Simulations Plus首席科学家，并参与学习的最新应用案例；6）您可免费获得一个月的GastroPlus软件试用。本次GastroPlus Workshop将让您受益良多：1）制药企业或CRO：有利于您理解您的客户或其他Sites实验方案设计思路、下一阶段决策及实验开展、合理设计实验方案；2）学术研究：启示您开辟新的药代、药剂等研究方向，剖析药物作用机制等；3）临床药理研究：合理设计临床试验方案，不同人群PK/PD研究等；4）法规部门：协助制定新药及仿制药政策和标准。报名方法：请您填写报名回执，并通过Email的方式反馈给我们。Email: training@pharmogo.com报名截止：2012年4月20日(北京培训班)/2012年4月30日(上海培训班)联系人：周伟,电话：021-61638583-8001报名确认：1）报名确认以凡默谷收到款项或报名者提供汇款凭证为准，凡默谷可先提供发票以供报销；2）会务组在接到报名后，将email或电话通知学员培训班相关事项。温馨提醒：学员必须自带已安装好Gastroplus程序的电脑参加培训，现场不提供电脑。
GastroPlus Workshop Course Instructors List
培训班详情：请下载附件参加北京培训班请点击下载：GastroPlus北京培训班第二轮通知/BeiJing GastroPlus-Intro-Workshop 2nd Notice参加北京培训班请点击下载：GastroPlus上海培训班第二轮通知/ShangHai GastroPlus-Intro-Workshop 2nd Notice
Michael B. Bolger
Chief Scientist
Simulations Plus Inc.
Dr. Bolger is Chief Scientist at Simulations Plus, he oversees a team of scientist / programmers at Simulations Plus, Inc. (Lancaster, CA) in the development of software programs (ADMET Predictor/Modeler, MedChem Studio/Designer, GastroPlus, DDDPlus, and MembranePlus) for estimation of biopharmaceutical properties, simulations of absorption and bioavailability, automated generation QSP/AR model building, in vitro dissolution, and cell culture permeability simulation.
As a faculty member at USC School of Pharmacy, his research was supported by several NIH basic science research grants and he published over 50 peer-reviewed publications. From 1989-1991 he served as a FDA National Science Advisor. He has served as a reviewer for numerous scientific publications. He is currently Adjunct Associate Professor of Pharmaceutical Sciences at USC.
Haiying Zhou, Ph.D.
Senior Scientist II
Simulations Plus Inc.
Dr. Zhou is Senior Scientist II at Simulations Plus, she focused on the development of modeling and simulation software for quantitative understanding of the pharmacokinetics and pharmacodynamics of drug candidates (GastroPlus), in vitro dissolution of active pharmaceutical ingredients and formulation excipients under various experimental conditions (DDDPlus). She received her M.S. degree in automation from East China University of Science and Technology (ECUST) in 2002 and her Ph.D in Biomedical Engineering from Case Western Reserve University (CWRU) in 2009. Her research interests in CWRU include multi-scale mathematical modeling of gas transport and cellular metabolism with emphasis on the metabolic regulation during different conditions, e.g. hypoxia and exercise.
John DiBella
Vice President of Marketing Simulations Plus Inc.
John DiBella is the Director – Marketing & Sales at Simulations Plus, He joined Simulations Plus in 2003 and has spent time working on the development of GastroPlus? and DDDPlus? software and consulting projects. Now, he leads the marketing & sales activities for the company while continuing to travel the world hosting training seminars.John obtained B.S. and M.S. degrees (with honors) in Biomedical Engineering from Case Western Reserve University in 2003. His graduate research was focused on computational modeling of physiological systems.
-
2012.09.19 首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
北京·2012年5月16-18日
上海·2012年5月21-23日尊敬的老师，您好！生理药代动力学模型（PBPK）在药物研发与监管中得到广泛应用意味着新时代的来临！它改变了动物试验和人体实验传统研究模式流程，指导制药企业项目决策及效率提高；FDA和EMA的使用及推荐，促使国外制药企业及学术单位相关研究者都在学习及掌握PBPK的应用。为促进我国在该领域的发展，力争与全球同步，凡默谷特邀美国Simulations Plus顶尖专家来华授课，让您了解及掌握PBPK知识、获悉国外最新应用、亲授多年使用经验，授课过程将以理论与实践相结合的形式进行。GastroPlus是由美国Simulations Plus公司研发的基于机制性生理模型的药代动力学、药效动力学(PBPK/PD)模拟软件，目前在FDA和几乎所有的全球顶尖制药公司中得到广泛应用，被誉为同类软件中的“黄金标准”。为确保培训效果，限额50人/班，第一轮通知发出后，已得到广大中国用户的积极响应和踊跃报名。报名从速！为何本次GastroPlus Workshop值得您参加？1）药物研发及监管中争相应用PBPK模型的时代已经来临！2）PBPK辅助药物研究可方便指导项目决策、节约成本、缩短时间；3）FDA已广泛采用PBPK模拟来制定法规和对新药及仿制药进行审批；4）FDA及各大制药企业对全球最权威的PBPK模拟软件GastroPlus倍加青睐；5）零距离接触Simulations Plus首席科学家，并参与学习的最新应用案例；6）您可免费获得一个月的GastroPlus软件试用。本次GastroPlus Workshop将让您受益良多：1）制药企业或CRO：有利于您理解您的客户或其他Sites实验方案设计思路、下一阶段决策及实验开展、合理设计实验方案；2）学术研究：启示您开辟新的药代、药剂等研究方向，剖析药物作用机制等；3）临床药理研究：合理设计临床试验方案，不同人群PK/PD研究等；4）法规部门：协助制定新药及仿制药政策和标准。报名方法：请您填写报名回执，并通过Email的方式反馈给我们。Email: training@pharmogo.com报名截止：2012年4月20日(北京培训班)/2012年4月30日(上海培训班)联系人：周伟,电话：021-61638583-8001报名确认：1）报名确认以凡默谷收到款项或报名者提供汇款凭证为准，凡默谷可先提供发票以供报销；2）会务组在接到报名后，将email或电话通知学员培训班相关事项。温馨提醒：学员必须自带已安装好Gastroplus程序的电脑参加培训，现场不提供电脑。
GastroPlus Workshop Course Instructors List
培训班详情：请下载附件参加北京培训班请点击下载：GastroPlus北京培训班第二轮通知/BeiJing GastroPlus-Intro-Workshop 2nd Notice参加北京培训班请点击下载：GastroPlus上海培训班第二轮通知/ShangHai GastroPlus-Intro-Workshop 2nd NoticeMichael B. Bolger
Chief Scientist
Simulations Plus Inc.
Dr. Bolger is Chief Scientist at Simulations Plus, he oversees a team of scientist / programmers at Simulations Plus, Inc. (Lancaster, CA) in the development of software programs (ADMET Predictor/Modeler, MedChem Studio/Designer, GastroPlus, DDDPlus, and MembranePlus) for estimation of biopharmaceutical properties, simulations of absorption and bioavailability, automated generation QSP/AR model building, in vitro dissolution, and cell culture permeability simulation.
As a faculty member at USC School of Pharmacy, his research was supported by several NIH basic science research grants and he published over 50 peer-reviewed publications. From 1989-1991 he served as a FDA National Science Advisor. He has served as a reviewer for numerous scientific publications. He is currently Adjunct Associate Professor of Pharmaceutical Sciences at USC.
Haiying Zhou, Ph.D.
Senior Scientist II
Simulations Plus Inc.
Dr. Zhou is Senior Scientist II at Simulations Plus, she focused on the development of modeling and simulation software for quantitative understanding of the pharmacokinetics and pharmacodynamics of drug candidates (GastroPlus), in vitro dissolution of active pharmaceutical ingredients and formulation excipients under various experimental conditions (DDDPlus). She received her M.S. degree in automation from East China University of Science and Technology (ECUST) in 2002 and her Ph.D in Biomedical Engineering from Case Western Reserve University (CWRU) in 2009. Her research interests in CWRU include multi-scale mathematical modeling of gas transport and cellular metabolism with emphasis on the metabolic regulation during different conditions, e.g. hypoxia and exercise.
John DiBella
Vice President of Marketing Simulations Plus Inc.
John DiBella is the Director – Marketing & Sales at Simulations Plus, He joined Simulations Plus in 2003 and has spent time working on the development of GastroPlus? and DDDPlus? software and consulting projects. Now, he leads the marketing & sales activities for the company while continuing to travel the world hosting training seminars.John obtained B.S. and M.S. degrees (with honors) in Biomedical Engineering from Case Western Reserve University in 2003. His graduate research was focused on computational modeling of physiological systems.